Hanson Pharmaceuticals (03692) has marketed innovative drugs, and all approved indications have been included in the medical insurance catalogue

Zhitongcaijing · 1d ago

Zhitong Finance App News, Hanson Pharmaceuticals (03692) announced that the Group's innovative drug Amelot® added one new indication and Xinyue® added two new indications successfully included in the new “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2026)”. The new national catalogue will be officially implemented on January 1, 2027.

In addition, the remaining four indications of the Group's innovative drug ametinib mesylate tablets (trade name: Ameilox®), the remaining indications of inelizumab injection (trade name: Xinyue®), and flumatinib mesylate tablets (trade name: Hausen Xinfu®) were renewed and included in the 2026 national health insurance catalogue, and polyethylene glycol losenatide injections (trade name: Freimax®) were renewed and included in the 2026 national health insurance list and expanded the scope of medical insurance payments; pemoxatide injections (trade name: Saint Rollei®) and aminotinol Currently, fuvir tablets (trade name: Hengmu®) are still within the national medical insurance catalogue agreement period. The agreement is valid until December 31, 2027; morpholinidazole sodium chloride injection (trade name: Melinda®) has been included in category B of the national health insurance routine catalogue. All approved indications for innovative drugs marketed by the Group have been included in the medical insurance catalogue, which helps to further improve the affordability and accessibility of various innovative drugs among patients.